These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Secondary mania associated with the use of felbamate. Hill RR; Stagno SJ; Tesar GE Psychosomatics; 1995; 36(4):404-6. PubMed ID: 7652143 [No Abstract] [Full Text] [Related]
28. Criteria for use of felbamate in adult, adolescent, and child inpatients and outpatients. Luer MS Am J Hosp Pharm; 1994 Jul; 51(13):1701-3; Quiz 1704-5. PubMed ID: 7942896 [No Abstract] [Full Text] [Related]
29. Status epilepticus induced by Felbatol withdrawal. DeGiorgio CM; Lopez JE; Lekht ZN; Rabinowicz AL Neurology; 1995 May; 45(5):1021-2. PubMed ID: 7746379 [No Abstract] [Full Text] [Related]
37. Felbamate in epilepsy therapy: evaluating the risks. Pellock JM Drug Saf; 1999 Sep; 21(3):225-39. PubMed ID: 10487399 [TBL] [Abstract][Full Text] [Related]
38. Neuropsychiatric side effects related to treatment with felbamate. McConnell H; Snyder PJ; Duffy JD; Weilburg J; Valeriano J; Brillman J; Cress K; Cavalier J J Neuropsychiatry Clin Neurosci; 1996; 8(3):341-6. PubMed ID: 8854308 [TBL] [Abstract][Full Text] [Related]
39. The new anticonvulsant drugs. Implications for avoidance of adverse effects. Schmidt D; Krämer G Drug Saf; 1994 Dec; 11(6):422-31. PubMed ID: 7727052 [TBL] [Abstract][Full Text] [Related]
40. Single-dose pharmacokinetics of felbamate in patients with renal dysfunction. Glue P; Sulowicz W; Colucci R; Banfield C; Pai S; Lin C; Affrime MB Br J Clin Pharmacol; 1997 Jul; 44(1):91-3. PubMed ID: 9241102 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]